The estimated Net Worth of Klaus W. Wagner is at least $8.13 Milhão dollars as of 16 February 2021. Dr Wagner owns over 176,033 units of Inhibrx stock worth over $3,227,250 and over the last 4 years he sold INBX stock worth over $4,300,486. In addition, he makes $600,074 as Chief Medical Officer & Exec. VP at Inhibrx.
Sign up
Dr Wagner INBX stock SEC Form 4 insiders trading
Dr has made over 1 trades of the Inhibrx stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 176,033 units of INBX stock worth $4,300,486 on 16 February 2021.
The largest trade he's ever made was selling 176,033 units of Inhibrx stock on 16 February 2021 worth over $4,300,486. On average, Dr trades about 88,017 units every 0 days since 2021. As of 16 February 2021 he still owns at least 215,150 units of Inhibrx stock.
You can see the complete history of Dr Wagner stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Dr. Klaus W. Wagner biography
Dr. Klaus W. Wagner is the Chief Medical Officer & Exec. VP at Inhibrx.
What is the salary of Dr Wagner?
As the Chief Medical Officer & Exec. VP of Inhibrx, the total compensation of Dr Wagner at Inhibrx is $600,074. There are 1 executives at Inhibrx getting paid more, with Mark Paul Lappe having the highest compensation of $994,281.
How old is Dr Wagner?
Dr Wagner is 48, he's been the Chief Medical Officer & Exec. VP of Inhibrx since . There are 2 older and 2 younger executives at Inhibrx. The oldest executive at Inhibrx, Inc. is Mark Paul Lappe, 54, who is the Founder, Chairman, Pres & CEO.
What's Dr Wagner's mailing address?
Klaus's mailing address filed with the SEC is C/O INHIBRX, INC., 11025 NORTH TORREY PINES ROAD, SUITE 200, LA JOLLA, CA, 92037.
Insiders trading at Inhibrx
Over the last 4 years, insiders at Inhibrx have traded over $27,711,393 worth of Inhibrx stock and bought 2,717,119 units worth $64,845,764 . The most active insiders traders include Global Investors Lp Viking ..., Capital Management, L.P.Kol..., eGlobal Investors Lp Viking .... On average, Inhibrx executives and independent directors trade stock every 42 days with the average trade being worth of $1,598,400. The most recent stock trade was executed by Mark Lappe on 6 September 2024, trading 44,000 units of INBX stock currently worth $671,000.
What does Inhibrx do?
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also provides INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company was founded in 2010 and is headquartered in La Jolla, California.
What does Inhibrx's logo look like?
Complete history of Dr Wagner stock trades at Inhibrx
Inhibrx executives and stock owners
Inhibrx executives and other stock owners filed with the SEC include:
-
Mark Paul Lappe,
Founder, Chairman, Pres & CEO -
Dr. Klaus W. Wagner,
Chief Medical Officer & Exec. VP -
Dr. Brendan P. Eckelman Ph.D.,
Founder, Chief Scientific Officer & Exec. VP of Corp. Strategy -
Kelly Devine Deck B.S., CPA, M.S.,
Chief Financial Officer -
Klaus Wagner,
Executive Vice President, Chief Medical Officer -
Kelly Deck,
Chief Financial Officer -
Quinn Deveraux,
Co-Founder, Executive Vice President - Early Research -
Brendan Eckelman,
Co-Founder, Executive Vice President - Corporate Strategy, Chief Scientific Officer -
Mark Lappe,
Chairman of the Board, Chief Executive Officer, Founder -
David Matly M.B.A.,
Exec. VP & Chief Commercial Officer -
Jeffrey J. Jensen,
Exec. VP of Clinical Operations -
Leah Pollema J.D.,
VP, Corp. Sec. & Gen. Counsel -
Dr. Ashraf Amanullah,
Exec. VP & Chief Technical Operations Officer -
Capital Management, L.P.Kol...,
-
Brendan P. Eckelman,
Chief Scientific Officer -
Jon Faiz Kayyem,
Director -
Global Investors Lp Viking ...,
-
Kristiina Md Vuori,
Director -
Douglas Forsyth,
Director -
Kimberly Manhard,
Director -
Global Investors Lp Viking ...,
-
Inc. Inhibrx,,
-
Mark Lappe,
Chief Executive Officer